Demand for weight-loss drugs is rising quickly in India as more people deal with obesity and diabetes, according to new data from research firm Pharmarack.
Eli Lilly’s Mounjaro, launched in late March, saw its sales double in June to nearly 88,000 units, earning 260 million rupees. From March to May, it had sold over 81,000 units. Meanwhile, Novo Nordisk’s Wegovy, launched in late June, sold around 1,800 units and made 25 million rupees.
India has one of the world’s highest obesity rates. Since 2021, the obesity drug market in the country has grown five times and is now worth 6.28 billion rupees.
Semaglutide, the main ingredient in Wegovy, leads the market with a two-thirds share, while tirzepatide, used in Mounjaro, holds about 8%. The semaglutide market alone is valued at 4.12 billion rupees.
Experts say more Indians are willing to try new obesity drugs due to rising awareness and affordability. However, Wegovy’s patent will expire in 2026, opening the door for cheaper generic versions.
Both drugs help users feel full longer and control blood sugar, making them effective for weight loss.
